Does belatacept improve outcomes for kidney transplant recipients? A systematic review

Transplant International

Volumn 28, Issue 11, 2015, Pages 1251-1264

  Talawila, Nishanthi ^a   Pengel, Liset H M ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

belatacept; calcineurin inhibitor; cyclosporine; immunosuppression; kidney transplantation; tacrolimus

Indexed keywords

BELATACEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ABATACEPT; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; COMPARATIVE STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ADULT; BLOOD; BLOOD PRESSURE; DIASTOLE; FEMALE; MALE; MIDDLE AGED; ODDS RATIO; PROCEDURES; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

ABATACEPT; ADULT; BLOOD PRESSURE; CALCINEURIN INHIBITORS; CHOLESTEROL, LDL; DIASTOLE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84931073842     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12605     Document Type: Review

References (32)

1. Meier-Kriesche H, Schold J, Srinivas T, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450.
3. Shirali AC, Bia MJ,. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3: 491.
4. Hamdy AF, El-Agroudy AE, Bakr MA, et al,. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005; 5: 2531.
5. Oberbauer R, Segoloni G, Campistol JM, et al,. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
6. Larsen CP, Pearson TC, Adams AB, et al,. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
7. Nulojix (belatacept) prescribing information. 2014 [updated May 2014 19/06/14]; Available from: http://packageinserts.bms.com/pi/pi-nulojix.pdf.
8. Sayed BA, Kirk AD, Pearson T, Larsen C,. Belatacept. In:, Morris PJ, Knechtle S, eds. Kidney Transplantation: Principles and Practice, 7th edn. Philadelphia: Elsevier, 2013: 314-319.
9. Martin S, Tsapepas D, Garbardi S, Chandraker A,. Critical appraisal of belatacept for prophylaxis of rejection in kidney transplant patients. Transplant Risk Manag 2011; 3: 65.
10. Su VCH, Harrison J, Rogers C, Ensom MHH,. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother 2012; 46: 57.
11. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (benefit-ext study). Am J Transplant 2010; 10: 547.
12. Ferguson R, Grinyo J, Vincenti F, et al,. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11: 66.
13. Rostaing L, Massari P, Garcia V, et al,. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430.
14. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (benefit study). Am J Transplant 2010; 10: 535.
15. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
16. Higgins JP, Altman DG, Gotzsche PC, et al,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
17. Sterne J, Egger M, Moher D,. Cochrane Handbook for Systematic Reviews of Interventions. In:, Higgins JPT, Green S, eds. Cochrane Book Series. Chichester: Wiley-Blackwell, 2009: 310-319.
18. Newell K, Mannon R, Mehta A, et al,. Long-Term Calcineurin Inhibitor (CNI) and Corticosteroid (CS) Avoidance Using Belatacept: The CTOT-10 Experience [abstract]. American Transplant Congress 2013 Seattle, WA, May 18-22 2013.
19. Rostaing L, Vincenti F, Grinyo J, et al,. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875.
20. Charpentier B, Medina Pestana JO, Del CRM, et al,. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013; 13: 2884.
21. Vincenti F, Blancho G, Durrbach A, et al,. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587.
22. Larsen CP, Grinyo J, Medina-Pestana J, et al,. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 12: 1528.
23. Grinyo J, Alberu J, Contieri FL, et al,. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int 2012; 25: 1059.
24. Dobbels F, Wong S, Min Y, Sam J, Kalsekar A,. Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation 2014; 98: 960.
25. Gill JS, Tonelli M, Mix CH, Pereira BJ,. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636.
26. Meier-Kriesche HU, Baliga R, Kaplan B,. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
27. McQuarrie EP, Jardine A,. Cardiovascular disease in renal transplantation. In:, Morris PJ, Knechtle S, eds. Kidney Transplantation: Principles and Practice, 7th edn. Philadelphia: Elsevier, 2013: 472.
28. Allen U, Preiksaitis J,. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 4): S87.
29. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J,. Summary of the US FDA approval of belatacept. Am J Transplant 2012; 12: 554.
30. Therapeutic Class Review. Immunosuppressants: Kidney Transplant-Focus on:belatacept (Nulojix). 2011 [Cited 2014 19/06/14]; Available from: http://www.regencerx.com/docs/physicianRx/immunosuppressants-nulojix-1011.pdf.
31. McDevitt-Potter L, Sadaka B, Tichy EM, Rogers CC, Gabardi S,. A multicenter experience with generic tacrolimus conversion. Transplantation 2011; 92: 653.
32. Bristol Myer Squibb. Subcutaneous Pharmacokinetics Study. 2007 [cited 2015 27/02/15]; Available from: https://clinicaltrials.gov/ct2/show/NCT00569803.